

Tetsuya Maeda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4366579/publications.pdf>

Version: 2024-02-01

55
papers

1,934
citations

279798

23
h-index

265206

42
g-index

60
all docs

60
docs citations

60
times ranked

2407
citing authors

#	ARTICLE	IF	CITATIONS
1	Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. <i>NeuroReport</i> , 1999, 10, 631-634.	1.2	288
2	<scp>Meta-Analysis</scp> of Gut Dysbiosis in Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1626-1635.	3.9	208
3	Progression of Parkinson's disease is associated with gut dysbiosis: Two-year follow-up study. <i>PLoS ONE</i> , 2017, 12, e0187307.	2.5	195
4	Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered L-DOPA. <i>Brain Research</i> , 2005, 1046, 230-233.	2.2	114
5	Reserpine Pretreatment Prevents Increases in Extracellular Striatal Dopamine Following L-DOPA Administration in Rats with Nigrostriatal Denervation. <i>Journal of Neurochemistry</i> , 2001, 74, 263-269.	3.9	80
6	A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease. <i>Neuroscience Research</i> , 2005, 52, 185-194.	1.9	74
7	Rapid induction of serotonergic hyperinnervation in the adult rat striatum with extensive dopaminergic denervation. <i>Neuroscience Letters</i> , 2003, 343, 17-20.	2.1	71
8	Cerebral circulation in aging. <i>Ageing Research Reviews</i> , 2016, 30, 49-60.	10.9	64
9	Short-Chain Fatty Acid-Producing Gut Microbiota Is Decreased in Parkinson's Disease but Not in Rapid-Eye-Movement Sleep Behavior Disorder. <i>MSystems</i> , 2020, 5, .	3.8	63
10	Upregulation of striatal adenosine A2A receptor mRNA in 6-hydroxydopamine-lesioned rats intermittently treated with L-DOPA. <i>Synapse</i> , 2004, 52, 218-222.	1.2	49
11	Beneficial Effects of Ramelteon on Rapid Eye Movement Sleep Behavior Disorder Associated with Parkinson's Disease - Results of a Multicenter Open Trial. <i>Internal Medicine</i> , 2016, 55, 231-236.	0.7	47
12	Study design and baseline characteristics of a population-based prospective cohort study of dementia in Japan: the Japan Prospective Studies Collaboration for Aging and Dementia (JPSC-AD). <i>Environmental Health and Preventive Medicine</i> , 2020, 25, 64.	3.4	47
13	Clinical manifestations of nonmotor symptoms in 1021 Japanese Parkinson's disease patients from 35 medical centers. <i>Parkinsonism and Related Disorders</i> , 2017, 38, 54-60.	2.2	45
14	Effects of yokukansan on behavioral and psychological symptoms of vascular dementia: An open-label trial. <i>Phytomedicine</i> , 2012, 19, 524-528.	5.3	44
15	Intestinal <i>Collinsella</i> may mitigate infection and exacerbation of COVID-19 by producing ursodeoxycholate. <i>PLoS ONE</i> , 2021, 16, e0260451.	2.5	42
16	Expression of metabotropic glutamate receptor mRNAs in the human spinal cord: implications for selective vulnerability of spinal motor neurons in amyotrophic lateral sclerosis. <i>Journal of the Neurological Sciences</i> , 2001, 189, 65-69.	0.6	36
17	Novel locus for benign hereditary chorea with adult onset maps to chromosome 8q21.3 q23.3. <i>Brain</i> , 2007, 130, 2302-2309.	7.6	34
18	Impaired metabolism of kynurenine and its metabolites in CSF of parkinson's disease. <i>Neuroscience Letters</i> , 2020, 714, 134576.	2.1	32

#	ARTICLE	IF	CITATIONS
19	Clinical diagnosis of vascular dementia. <i>Journal of the Neurological Sciences</i> , 2007, 257, 44-48.	0.6	31
20	Parkinson's disease comorbid with narcolepsy presenting low CSF hypocretin/orexin level. <i>Sleep Medicine</i> , 2006, 7, 662.	1.6	29
21	Ischemia Alters the Expression of Connexins in the Aged Human Brain. <i>Journal of Biomedicine and Biotechnology</i> , 2009, 2009, 1-8.	3.0	28
22	Validity and Reliability Assessment of a Japanese Version of the Snaith-Hamilton Pleasure Scale. <i>Internal Medicine</i> , 2012, 51, 865-869.	0.7	26
23	Randomized, double-blind, multicenter trial of hydrogen water for Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1505-1507.	3.9	26
24	Randomized, Controlled Study of Opicapone in Japanese Parkinson's Patients with Motor Fluctuations. <i>Movement Disorders</i> , 2021, 36, 415-423.	3.9	24
25	Multicentre multiobserver study of diffusion-weighted and fluid-attenuated inversion recovery MRI for the diagnosis of sporadic Creutzfeldt-Jakob disease: a reliability and agreement study. <i>BMJ Open</i> , 2012, 2, e000649.	1.9	23
26	A randomized double-blind multi-center trial of hydrogen water for Parkinson's disease: protocol and baseline characteristics. <i>BMC Neurology</i> , 2016, 16, 66.	1.8	23
27	Anhedonia and its correlation with clinical aspects in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2017, 372, 403-407.	0.6	20
28	Amantadine increases l-DOPA-derived extracellular dopamine in the striatum of 6-hydroxydopamine-lesioned rats. <i>Brain Research</i> , 2003, 972, 229-234.	2.2	19
29	Cerebrovascular lesions in elderly Japanese patients with Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2012, 322, 87-91.	0.6	16
30	Acute cerebellar ataxia due to Epstein-Barr virus under administration of an immune checkpoint inhibitor. <i>BMJ Case Reports</i> , 2019, 12, e231520.	0.5	16
31	High Prevalence of Gastroesophageal Reflux Disease in Parkinson's Disease: A Questionnaire-Based Study. <i>Parkinson's Disease</i> , 2013, 2013, 1-6.	1.1	14
32	Altered gut microbiota in Parkinson's disease patients with motor complications. <i>Parkinsonism and Related Disorders</i> , 2022, 95, 11-17.	2.2	10
33	Real-World Nonmotor Changes in Patients with Parkinson's Disease and Motor Fluctuations: J-FIRST. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 431-439.	1.5	9
34	A Japanese multicenter survey characterizing pain in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2016, 365, 162-166.	0.6	8
35	Exogenous l-DOPA induce no dopamine immuno-reactivity in striatal astroglia and microglia of adult rats with extensive nigro-striatal dopaminergic denervation. <i>Neuroscience Letters</i> , 2008, 433, 255-258.	2.1	7
36	Rhinorrhea in Parkinson's disease: A consecutive multicenter study in Japan. <i>Journal of the Neurological Sciences</i> , 2014, 343, 88-90.	0.6	6

#	ARTICLE	IF	CITATIONS
37	Differentiation Between Multiple System Atrophy and Other Spinocerebellar Degenerations Using Diffusion Kurtosis Imaging. <i>Academic Radiology</i> , 2019, 26, e333-e339.	2.5	6
38	Long-term safety and efficacy of opicapone in Japanese Parkinson's patients with motor fluctuations. <i>Journal of Neural Transmission</i> , 2021, 128, 337-344.	2.8	6
39	Superb Microvascular Imaging Ultrasound for Cervical Carotid Artery Stenosis for Prediction of the Development of Microembolic Signals on Transcranial Doppler during Carotid Exposure in Endarterectomy. <i>Cerebrovascular Diseases Extra</i> , 2021, 11, 61-68.	1.5	5
40	Cerebrospinal fluid levels of oxidative stress measured using diacron-reactive oxygen metabolites and biological antioxidant potential in patients with Parkinson's disease and progressive supranuclear palsy. <i>Neuroscience Letters</i> , 2021, 757, 135975.	2.1	5
41	Influence of istradefylline on non-motor symptoms of Parkinson's disease: A subanalysis of a 1-year observational study in Japan (J-FIRST). <i>Parkinsonism and Related Disorders</i> , 2021, 91, 115-120.	2.2	5
42	Cross-sectional area of the vagus nerve on carotid duplex ultrasound and atrial fibrillation in acute stroke: A retrospective analysis. <i>ENeurologicalSci</i> , 2021, 25, 100378.	1.3	5
43	Increase of the striatal serotonergic fibers after nigrostriatal dopaminergic denervation in adult rats. <i>International Congress Series</i> , 2003, 1251, 211-215.	0.2	4
44	Research and development of a portable device to quantify muscle tone in patients with Parkinson's disease. , 2008, 2008, 2825-7.		4
45	Non-motor symptoms depending on motor severity in Japanese patients with Parkinson's disease: A multicenter cross-sectional study. <i>Journal of the Neurological Sciences</i> , 2020, 412, 116641.	0.6	4
46	Impact of Introducing the Pletaal Assist System on Drug Adherence in Outpatients with Ischaemic Stroke: A Pilot Study. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 835-841.	1.8	4
47	Vascular Imaging Techniques to Diagnose and Monitor Patients with Takayasu Arteritis: A Review of the Literature. <i>Diagnostics</i> , 2021, 11, 1993.	2.6	4
48	Personality traits associated with freezing of gait in Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2020, 81, 67-68.	2.2	2
49	Novel antithrombotic effects of dabigatran in patients with non-valvular atrial fibrillation. <i>Thrombosis Research</i> , 2020, 189, 1-4.	1.7	2
50	Sporadic Triple A (Allgrove) Syndrome with Novel Tandem Mutations. <i>Internal Medicine</i> , 2021, 60, 799-802.	0.7	2
51	Influence of PAR-1 in patients with non-valvular atrial fibrillation: The antiplatelet effect of dabigatran. <i>Thrombosis Research</i> , 2021, 201, 123-130.	1.7	2
52	l-DOPA-derived extracellular dopamine in the striatum with dopaminergic denervation: role of serotonergic neurons in l-DOPA metabolism. <i>International Congress Series</i> , 2003, 1251, 181-189.	0.2	1
53	Determination of the reference range of platelet aggregation using a new automatic coagulation analyzer and visualization of platelet function data. <i>Thrombosis Research</i> , 2020, 194, 95-97.	1.7	1
54	Discussion Meeting on Essential Knowledge of Parkinson's Disease for General Physicians. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2015, 104, 1597-1607.	0.0	0

#	ARTICLE	IF	CITATIONS
55	Inhibitory Effects of P2Y12 Receptor Antagonist on PAR1- and PAR4-AP-Induced Platelet Aggregation in Patients with Stroke or TIA. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105547.	1.6	0